TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTCRYPTOMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTERTECHNOLOGY
Search

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Wild Wall Street, Pot Stock Aphria, Sears' Final Hours? - 5 Things You Must Know
INVESTING

Sangamo Shares Soar as Hemophilia Drug Shows Promise

  • By Scott Van Voorhis
  • Jul 8, 2019 11:10 AM EDT
Nektar Therapeutics Just Lost More Than $6 Billion in Value Because of One Drug
STOCKS

Spark Therapeutics' Shares Misfire on Roche Acquisition Delay

  • By M. Corey Goldman
  • Jun 10, 2019 11:01 AM EDT
Roche Buys More Time in $4.3B Offer for Spark Therapeutics
INVESTING

Roche Buys More Time in $4.3B Offer for Spark Therapeutics

  • By M. Corey Goldman
  • Apr 3, 2019 9:43 AM EDT
Roku's Recent Surge Means It's a Good Time to Take Profits
STOCKS

Trading Roku Stock as Downgrades Sap Its Run to New Highs

  • By Bret Kenwell
  • Mar 13, 2019 1:20 PM EDT
Trump Announces Escalating Tariffs on China
JIM CRAMER

Win, With or Without China: Cramer's 'Mad Money' Recap

  • By Scott Rutt
  • Feb 25, 2019 8:57 PM EST
Flashback Friday: Relighting the Cannabis Craze
MARKETS

3 Things to Know at Market Close: ETF Inflows, Spark Therapeutics, Palo Alto

  • By Jacob Sonenshine
  • Feb 25, 2019 4:19 PM EST
Iran, Trump, Canopy Growth, Slack, Zion Williamson - 5 Things You Must Know
MARKETS

Dow Closes Modestly Higher After Trump Extends China Tariff Deadline

  • By Joseph Woelfel
  • Feb 25, 2019 4:06 PM EST
Roche Buys More Time in $4.3B Offer for Spark Therapeutics
STOCKS

Spark Therapeutics Rockets as Roche Pays $4.3 Billion for Gene Therapy Experts

  • By Martin Baccardax
  • Feb 25, 2019 11:37 AM EST
Dow Ends Sharply Higher Ahead of Trump-Xi Meeting at G-20
MARKETS

Trade Talks, Spark, Buffett, Kraft Heinz, 'Green Book' - 5 Things You Must Know

  • By Joseph Woelfel
  • Feb 25, 2019 8:05 AM EST
Dow Futures Flat, Global Stocks Retreat Amid Fading U.S.-China Trade Hopes
STOCKS

Stocks Gain, China Surges, as Trump Delays Tariffs Amid Trade Talk Progress

  • By Martin Baccardax
  • Feb 25, 2019 7:37 AM EST
Roche Buys More Time in $4.3B Offer for Spark Therapeutics
MARKETS

Roche to Buy Spark for $4.8 Billion

  • By Adam Smith
  • Feb 25, 2019 1:28 AM EST
Roche Buys More Time in $4.3B Offer for Spark Therapeutics
MARKETS

Roche Aims to Buy Spark for $5 Billion: Wall Street Journal

  • By Adam Smith
  • Feb 24, 2019 12:45 PM EST
3 Biotech Stock Favorites to Bet on Today: Top Analysts
STOCKS

3 Biotech Stock Favorites to Bet on Today: Top Analysts

  • By Tip Ranks
  • Aug 13, 2018 8:00 AM EDT
Novo Nordisk Makes Unsolicited Bid for Ablynx
STOCKS

7 Winners and Losers From Biggest Biotech Conference of 2017

  • By Tony Owusu
  • Dec 13, 2017 11:34 AM EST
Exact Sciences in Talks to Buy Genomic Health - Report
STOCKS

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment

  • By Bret Kenwell
  • Dec 11, 2017 12:23 PM EST
Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter
REGULATION

FDA Advisory Committee Greenlights First Gene Therapy For Inherited Disorder

  • By Bill Meagher
  • Oct 12, 2017 7:26 PM EDT
Mesoblast Soars on Stem-Cell Treatment Data
HEALTH

Illumina Shares Jump on Better-Than-Expected Second-Quarter Numbers

  • By Armie Margaret Lee
  • Aug 2, 2017 11:17 AM EDT
3 Health Care Stocks to Own for 2017
HEALTH

Celgene, Vertex and Spark Among Jefferies' Top Biotech Picks

  • By Armie Margaret Lee
  • Jul 14, 2017 4:11 PM EDT
Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
STOCKS

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

  • By Adam Feuerstein
  • Dec 5, 2016 1:11 PM EST
Hikma Shakes Up U.S. Operations After FDA Disappointment; CEO Said Darwazah to Lead Group
STOCKS

Spark's hemophilia gene therapy remains effective despite immune reactions

  • By Adam Feuerstein
  • Dec 3, 2016 1:04 PM EST
Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
STOCKS

The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

  • By Adam Feuerstein
  • Nov 3, 2016 10:31 AM EDT
Jim Cramer's Top Takeaways: The Rubicon Project, GameStop, Delta Air Lines, Alcoa
OPINION

Jim Cramer's Top Takeaways: Spark Therapeutics, General Mills, Kellogg, ConAgra, Campbell

  • By Scott Rutt
  • Sep 9, 2016 6:00 AM EDT
Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week
JIM CRAMER

Jim Cramer's 'Mad Money' Recap: This Market Has a One-Track Mind

  • By Scott Rutt
  • Sep 8, 2016 8:16 PM EDT
Valeant Acquires Eyegate Licensing Rights
OPINION

13 companies to watch from MIT's smart 50 list, including 4 buys

  • By Robert Wasserman
  • Jul 21, 2016 7:48 AM EDT
Perilous Reversal Watch: Golar LNG (GLNG)
MARKETS

Strong On High Relative Volume: Spark Therapeutics (ONCE)

  • By TheStreet Wire
  • Jul 12, 2016 10:02 AM EDT
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.